Also known as WINREVAIR.
FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
Met primary endpoint with significant PVR reduction at 24 weeks vs placebo. Also favorable mPAP/PAWP, NT‑proBNP and 6MWD trends, delayed clinical worsening; safety consistent with known profile.
Merck shares positive Phase 3 and Phase 2 trial results for enlicitide and WINREVAIR™ at ACC.26, highlighting advancements in hypercholesterolemia and CpcPH-HFpEF research.
Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.
EU CHMP backs expanded WINREVAIR™ use for PAH, covering WHO FC II-IV. Decision by European Commission expected Q1 2026.
WINREVAIR reduced pulmonary vascular resistance in Phase 2 CADENCE study, supporting Phase 3 development for treating pulmonary hypertension due to heart failure with preserved ejection fraction.
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
WINREVAIR, when started within a year of PAH diagnosis, significantly lowers clinical worsening risk. Safety profile aligns with previous trials. Results shared at ERS 2025 and published in NEJM.
